Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized
by an acute deterioration in respiratory symptoms, are fundamental events impacting …
by an acute deterioration in respiratory symptoms, are fundamental events impacting …
Aerosol pulmonary immune engineering
ER Sudduth, M Trautmann-Rodriguez, N Gill… - Advanced Drug Delivery …, 2023 - Elsevier
Aerosolization of immunotherapies poses incredible potential for manipulating the local
mucosal-specific microenvironment, engaging specialized pulmonary cellular defenders …
mucosal-specific microenvironment, engaging specialized pulmonary cellular defenders …
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline
JD Chalmers, IF Laska, FME Franssen… - European …, 2020 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter …
Rationale: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation
therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts …
therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts …
Excess mucus viscosity and airway dehydration impact COPD airway clearance
VY Lin, N Kaza, SE Birket, H Kim… - European …, 2020 - Eur Respiratory Soc
The mechanisms by which cigarette smoking impairs airway mucus clearance are not well
understood. We recently established a ferret model of cigarette smoke-induced chronic …
understood. We recently established a ferret model of cigarette smoke-induced chronic …
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
CF Vogelmeier, M Gaga, M Aalamian-Mattheis… - Respiratory …, 2017 - Springer
Background Dual bronchodilation combining a long-acting β 2-agonist (LABA) and a long-
acting muscarinic antagonist (LAMA) is the preferred choice of treatment recommended by …
acting muscarinic antagonist (LAMA) is the preferred choice of treatment recommended by …
The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities
M Yamada, M Ichinose - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•The cholinergic anti-inflammatory pathway modulates inflammatory
responses.•The α7nAChR is the critical target on inflammatory cells in this pathway.•Recent …
responses.•The α7nAChR is the critical target on inflammatory cells in this pathway.•Recent …
[HTML][HTML] Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic …
NA Hanania, DP Tashkin, EM Kerwin, JF Donohue… - Respiratory …, 2017 - Elsevier
Background The long-term safety and efficacy of a novel Co-Suspension™ Delivery
Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination …
Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination …
Risk factors of postoperative pulmonary complications in patients with asthma and COPD
T Numata, K Nakayama, S Fujii, Y Yumino… - BMC pulmonary …, 2018 - Springer
Background Postoperative pulmonary complications (PPC) in patients with pulmonary
diseases remain to be resolved clinical issue. However, most evidence regarding PPC has …
diseases remain to be resolved clinical issue. However, most evidence regarding PPC has …
[HTML][HTML] Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD
FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - Chest, 2017 - Elsevier
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …